Immunome's Director Just Completed a $4.39 Million Two-Day Campaign
Immunome director Isaac Barchas sold 201,050 shares for $4.39M through ABHMC II LLC and Arsenal Bridge Venture II-B LLC under a March 2026 10b5-1 plan across two days at $21β$23. 311,763 shares retained.
π΄ Insider Activity Score: 88/100
Isaac Barchas, independent director of Immunome, filed a Form 4 on July 2, 2026 β a Thursday holiday-abridged wire β disclosing the completion of a two-day plan-governed distribution across two institutional vehicles: ABHMC II LLC and Arsenal Bridge Venture II-B LLC β selling 101,050 shares at a $21.12 average on day one and dual blocks at $22.35 and $23.33 on day two, combining for 201,050 aggregate shares and approximately $4,393,024 β governed by a Rule 10b5-1 plan adopted on March 31, 2026. Barchas retains 311,763 combined direct and indirect shares. The March plan ran both vehicles across both sessions. The ascending execution corridor is the venture fund lifecycle collecting appreciation across the two-day window.
The Dual-Vehicle Architecture: ABHMC II LLC and Arsenal Bridge Venture II-B LLC
The two institutional vehicles β ABHMC II LLC and Arsenal Bridge Venture II-B LLC β are the specific fund structures through which Barchas manages his Immunome equity exposure, reflecting the multi-entity venture capital portfolio architecture of a director affiliated with an institutional investment firm rather than a single personal account.
The naming convention of both vehicles β ABHMC II and Arsenal Bridge Venture II-B β suggests a common institutional family: sequential fund designations from the same investment platform, with both vehicles holding Immunome positions and executing synchronized distributions under the same March 31 plan. The simultaneous two-vehicle distribution is a fund-house capital return decision β both vehicles designated for proportional distribution in the same plan window β not two independent portfolio management judgments.
This series has documented the multi-vehicle synchronized architecture across the Basswood Dime Community dual-fund analysis, the Atlas Venture Kymera Fund X and Opportunity Fund I distribution, and the Insight Holdings Hinge Health 24-conversion event. The analytical conclusion is consistent: coordinated multi-vehicle distributions from the same plan reflect a single fund-house capital return decision implemented across parallel entity structures.
The March 31, 2026 Plan: Three Months of Temporal Insulation
The plan adoption date of March 31, 2026 β approximately three months before the July execution window β places the distribution decision outside the multi-month high environment that produced the $21 to $23 execution corridor.
In March 2026, the specific ascending price corridor β $21.12 on day one, $22.35 and $23.33 on day two β was not the available market context. The plan designated the execution window and share count targets that the two-day campaign delivered automatically. The ascending corridor across the two-day execution reflects the plan collecting natural price appreciation across successive sessions rather than a director timing the exit at the peak.
The Ascending Execution Corridor: $21.12 to $23.33
The two-day price progression β $21.12 opening session, $22.35 and $23.33 closing session β is the specific execution pattern of a plan running its designated sessions as the stock appreciated between day one and day two.
The day-one 101,050-share dominant block at $21.12 established the majority of the distribution. The day-two dual fills at $22.35 and $23.33 completed the plan's target at progressively higher prices β the plan collecting approximately $1.14 to $2.21 per share more on the second session than the first, not because the director made a timing decision but because the plan's calendar ran the second session as the market offered higher prices.
The 311,763 Retained Position: Venture Fund Thesis Anchor
The 201,050 shares distributed represent approximately 39.2% of the pre-sale combined position of approximately 512,813 shares β a meaningful proportional distribution that leaves 311,763 shares β approximately 60.8% of the combined position β intact across the direct and indirect account structures.
At $23.33, the retained 311,763 shares represent approximately $7.27 million in combined equity exposure to Immunome's oncology platform β the venture fund's ongoing commitment to the antibody-based cancer therapy thesis whose clinical progress has driven the multi-month valuation appreciation the March plan is harvesting.
About Immunome, Inc.
Immunome, Inc. is a clinical-stage oncology biopharmaceutical company developing antibody-based cancer therapies targeting tumor-associated antigens. Director Isaac Barchas retains 311,763 combined direct and indirect shares following the March 31, 2026 Rule 10b5-1 plan's two-day dual-vehicle distribution of 201,050 shares through ABHMC II LLC and Arsenal Bridge Venture II-B LLC for approximately $4,393,024. Immunome trades on the Nasdaq under the ticker IMNM.
How to Think About This
Barchas's two-day dual-vehicle campaign scores 88/100 β the alarm-management calibration for a venture capital director's $4.39 million plan-governed distribution at a clinical-stage oncology company near multi-month highs, with March plan insulation governing both vehicles across the ascending two-day corridor and 311,763 combined retained shares confirming 60.8% of the position remains invested in the antibody therapy thesis.
The March plan ran both vehicles. The ascending corridor delivered natural appreciation across two sessions. The 311,763 retained shares are the venture fund's ongoing oncology thesis anchor.